Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

OssDsign

9.25 SEK

+0.54 %

Less than 1K followers

OSSD

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

+0.54 %
-18.43 %
-18.00 %
-29.06 %
-38.66 %
-8.60 %
+58.66 %
-21.27 %
-46.77 %

OssDsign is a developer and supplier of orthobiological products. The company develops and markets products that support the body's own healing ability, such as OssDsign Catalyst, which is a nanosynthetic bone graft for dual bone formation pathways through fusion mass. The company offers its products around the global market. OssDsign was founded in 2011 and is headquartered in Uppsala.

Read more
Market cap
1.02B SEK
Turnover
3.29M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
3.2.
2026

Annual report '25

6.5.
2026

Interim report Q1'26

9.6.
2026

General meeting '26

ShowingAll content types
Third party research

OssDsign: FX drag masks solid growth - ABG

* 27% y-o-y organic sales growth in Q4'25e * No change to financial targets expected Q4'25 results due 3 February Q4'25 expectations We believe OssDsign will continue to deliver solid sales growth for Catalyst in the US and pencil in 27% organic growth...

OssDsign

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Third party research

OssDsign: New CEO appointed - ABG

* Mark Waugh appointed new CEO* Relevant background from orthapaedic industry* Supportive for sentiment Getting ready for the next phase OssDsign has appointed Mark Waugh as its new CEO, effective 1 January 2026. Waugh joins from Medacta USA, where he...

OssDsign
Third party research

OssDsign: Case intact despite slightly slower momentum - ABG

* Major beat on EBIT, but lower sales* Estimates up on adj. EBIT for '25e-'26e (lower loss), yet down for '27e* Fair value range down to SEK 10-17 (11-18)Continued operational leverage despite sales missOssDsign delivered a mixed set of numbers in Q3...

OssDsign
Third party research

OssDsign: Strong cost control in Q3 - ABG

* 35% organic sales growth in Q3 (ABGSCe +38%)Adj. EBIT +37% vs ABGSCe* No change in outlookQ3 resultsOssDsign reported a mixed set of numbers in Q3 with lower sales but strong cost control and operational leverage. Q3 sales came in at SEK 44.2m (-4%...

OssDsign
Third party research

OssDsign: Encouraging core despite near-term headwinds - ABG

* 38% y-o-y organic sales growth in Q3'25e* EBIT forecasts cut by 4.0-6.1% for '25e-'27e* Q3'25 results due 4 NovemberQ3'25 expectationsWe expect OssDsign to report Q3 sales of SEK 46.2m and EBIT of SEK -8.5m, implying continued solid sales momentum ...

OssDsign
Third party research

Ossdsign: Another solid step forward - ABG

- Strong growth and gross margin continued in Q2'25 -EBIT revised up by 11% for '25e and 4% for '26e-'27e - Fair value range narrowed to SEK 12-18 (10-18) Another strong set of numbers In Q2, OssDsign delivered an adj. EBIT beat of 28% vs. ABGSCe, driven...

OssDsign
Third party research

Ossdsign: Impressive sales growth - ABG

- Sales beat and higher gross margin - Adj. EBIT +28% vs ABGSCe - Estimates likely to be revised up 8-12% on EBIT '25e Q2 results OssDsign reported a strong set of numbers in Q2 with sales of SEK 46.5m (+11% vs ABGSCe SEK 41.8m, no consensus) and adj...

OssDsign
Third party research

Ossdsign: Cash injection supports growth - ABG

50% y-o-y organic sales growth in Q2'25e EBIT forecasts raised by 1.0-55.7% for '25e-'27e Q2'25 results due 19 August Q2'25 expectations We expect the positive sales momentum to have continued for OssDsign in Q2, driven by continued improved market access...

OssDsign
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.